CDKN1A and renal cell carcinoma: Currently, the best approach would be to target cytoplasmic p21, to inhibit its anti-apoptotic properties and to sensitize chemotherapy resistant cancer cells, as demonstrated in renal cell carcinoma [157] or breast cancer [14].